Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Percutaneous Heart Valves Tomorrow, Surgical Improvements Today

This article was originally published in Start Up

Executive Summary

According to a report just issued by Health Research International, "Opportunities in Heart Valve Disease Management: Europe, Japan, and Rest of World," sales of heart valves-both the percutaneous and surgical products-will increase almost 9% annually, to $900 million in 2010 in ex-US markets. Driving growth in the market will be a growing tendency to perform valve surgeries concomitantly with coronary artery bypass graft procedures, demographics (an increase in the aged), and emerging markets in developing countries.

You may also be interested in...



In Brief October 2006

Short summaries of notable clinical and product news items in the device industry.

Evalve: Leading the Valve Revolution

Full-scale commercialization of percutaneous heart valve technology is still years away, but Evalve's new approach to mitral repair is closest to the clinic.

In Heart Valves, The End of Watchful Waiting?

Health Research International has just issued a report, "US Opportunities in Heart Valve Disease Management." According to the report, the market for valve replacement and repair products will grow from more than $500 million in 2004 to some $900 million in 2010, with the greatest growth occurring in percutaneous valve products.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT037344

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel